KEY POINTS
  • The early data from Pfizer looked at blood samples taken from 40 people ages 18 to 55 and 40 people older than 55 who received the omicron booster.
  • Both age groups saw a substantial increase in antibodies that block the BA.5 subvariant from invading human cells.
  • The FDA has authorized Pfizer's boosters without direct human data on how they perform against the omicron BA.5 subvariant.
  • Pfizer said it will release more immune response data in the coming weeks.

In this article

Pfizer and its German partner BioNTech on Thursday said their new omicron boosters substantially increased protective antibodies against the dominant omicron BA.5 subvariant for adults in the first direct human data released to the public on the new shots.

The study looked at blood samples taken from 40 people ages 18 to 55 and 40 people older than 55 who received the omicron booster. Both age groups saw a substantial increase in antibodies that block the BA.5 subvariant from invading human cells, according to the companies.

In this article